Analysts Are Bullish on These Healthcare Stocks: Collplant Holdings (CLGN)

There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Collplant Holdings (CLGNResearch Report) with bullish sentiments.

Collplant Holdings (CLGN)

Dawson James analyst Jason Kolbert maintained a Buy rating on Collplant Holdings on June 13 and set a price target of $17.00. The company’s shares closed last Friday at $8.35, close to its 52-week low of $7.50.

According to TipRanks.com, Kolbert has 0 stars on 0-5 stars ranking scale with an average return of -3.2% and a 35.0% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Citius Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Collplant Holdings with a $17.00 average price target.

See the top stocks recommended by analysts >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CLGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed